AlphAIAlphAI — Financial news for AI agents
MeykaMAR 244 min read$IPHA

IPH.PA Innate Pharma S.A. EURONEXT 24 Mar 2026 intraday: earnings preview ahead

Innate Pharma S.A. (IPH.PA) stock is up 8.94% today as traders anticipate its earnings release on March 26, 2026. Key focuses for the earnings call will be updates on Phase III Monalizumab and Phase II Lacutamab clinical programs, cash runway, and potential partnership milestones. Meyka AI gives IPH.PA a "HOLD" rating with an estimated 18.80% upside, but highlights risks such as high debt-to-equity and potential dilution.

Original reporting
Meyka · Danny Kontos
Published Mar 24, 2026, 8:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 24, 2026, 9:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IPHA
Neutral
medium confidence
Mentioned
$IPHA
Relevance
6/10
AlphAI data visualization · based on Meyka
Decision brief

The 30-second read

$IPHANeutralMed
01

Why it matters

Earnings results could significantly influence stock trajectory, especially if clinical updates or financials differ from expectations.

02

Market read

The upcoming earnings are a key event for Innate Pharma, with potential sector-wide implications depending on the results.

03

What to watch

Potential dilution from upcoming financings or debt refinancing could negatively impact stock value.

Relevance 6/10Timing: High, as the earnings release is scheduled for March 26, 2026.

Background

Innate Pharma is a biotech company focusing on immuno-oncology therapies, with ongoing clinical trials for Monalizumab and Lacutamab.

Company-level read

Ticker impact

$IPHANeutralMedium confidence
Context

The stock's movement is driven by anticipation of upcoming earnings release on March 26, 2026.

Expected impact

Potential short-term upward movement leading into earnings, with possible volatility post-announcement.

Evidence & confidence

The stock's rise is based on trader anticipation rather than confirmed news, and earnings results could diverge from expectations, introducing volatility.

Market effects

Sector

Potential positive impact on biotech and life sciences sectors due to clinical program updates.

Regional

Limited regional impact; primarily relevant to European biotech markets.

Global

Moderate, as biotech sector developments can influence global biotech indices.

Counterpoint

What could challenge this read

Earnings may disappoint if clinical updates are less favorable, leading to a sharp decline.

Key entities

  • Company
    Innate Pharma S.A.

    A biotech firm specializing in immuno-oncology therapies.

  • Clinical Program
    Monalizumab

    A Phase III immunotherapy drug candidate for cancer treatment.

  • Clinical Program
    Lacutamab

    A Phase II therapy targeting specific cancer types.

Read at source← All news

Related articles

OCT 27
$AZNMed

AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027

Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.

investing.com1 min
SEP 18
$IPHAMed

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.

aol.com2 min
SEP 17
$IPHAMed

Innate Pharma SA: Innate Pharma Reports First Half 2026 Business Update and Financial Results

Innate Pharma reported its first half 2026 results, highlighting a strategic partnership with Sobi for lacutamab, a $75M upfront payment, and a €30M equity financing. Key milestones include the initiation of the TELLOMAK-3 Phase 3 trial for lacutamab, expected to report data in Q1 2027, and the presentation of IPH4502 Phase 1 data at ENA 2026. The company also anticipates a PACIFIC-9 Phase 3 readout for monalizumab by year-end. As of June 30, 2026, Innate Pharma had a cash position of €21.4M and

finanznachrichten.de3 min
SEP 17
$IPHAMedAI 8/10

Sobi and Innate announce partnership is now effective following completion of closing conditions

Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma (IPH, IPHA) announced their strategic partnership is now effective. Sobi will pay Innate $75 million upfront, with potential milestone payments up to $465 million. Innate will conduct a Phase 3 trial for lacutamab, a treatment for cutaneous T-cell lymphoma, with Sobi receiving exclusive commercialization rights.

prnewswire.com2 min